CCN6: a modulator of breast cancer progression
Author:
- 16 April 2016
- journal article
- review article
- Published by Wiley in Journal of Cell Communication and Signaling
- Vol. 10 (2) , 163-164
Abstract
The expression of the CCN family of matricellular proteins is highly dysregulated in connective tissue pathologies such as fibrosis and highly metastatic cancers. Strategies targeting members of this family, especially CCN2, are under development as novel therapeutic approaches to highly metastatic cancers such as pancreatic cancer. In prior reports, the Kleer laboratory and colleagues have linked reduced expression of CCN6 (WISP3) with aggressive breast cancers. Loss of CCN6 was associated with elevated Akt phosphorylation and TAK1 activation. In a recent report, the same group reports that, by modulating Notch signaling, CCN6 can promote the maintenance of an epithelial phenotype and also reduce cancer cell migration and invasion, tumor initiation, and metastasis (Oncotarget in press DOI: 10.18632/oncotarget.7734 ). These results are consistent with the hypothesis that addition of CCN6 peptides may represent a novel, viable therapeutic approach to blocking aggressive breast cancers.Keywords
This publication has 11 references indexed in Scilit:
- The matricellular protein CCN6 (WISP3) decreases Notch1 and suppresses breast cancer initiating cellsOncotarget, 2016
- CCN2 Expression by Tumor Stroma Is Required for Melanoma MetastasisJournal of Investigative Dermatology, 2015
- Use of Proteins as Biomarkers and Their Role in CarcinogenesisJournal of Cancer, 2015
- CCN6 Modulates BMP Signaling via the Smad-Independent TAK1/p38 Pathway, Acting to Suppress Metastasis of Breast CancerCancer Research, 2012
- Dysregulated expression of Slug, vimentin, and E‐cadherin correlates with poor clinical outcome in patients with basal‐like breast cancerJournal of Surgical Oncology, 2012
- Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targetsNature Reviews Drug Discovery, 2011
- Association of the metastatic phenotype with CCN family members among breast and oral cancer cellsJournal of Cell Communication and Signaling, 2011
- Blockade of CCN6 (WISP3) Activates Growth Factor–Independent Survival and Resistance to Anoikis in Human Mammary Epithelial CellsCancer Research, 2010
- Inhibition of CCN6 (Wnt-1-Induced Signaling Protein 3) Down-Regulates E-Cadherin in the Breast Epithelium through Induction of Snail and ZEB1The American Journal of Pathology, 2008
- Matricellular proteins: extracellular modulators of cell functionCurrent Opinion in Cell Biology, 2002